A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10.

Abstract

The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

Keywords: Adoptive cell therapy; Checkpoint inhibitor; Clinical trials; Immune-related adverse events; Immunotherapy; Targeted therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use
  • Female
  • Genital Neoplasms, Female / immunology*
  • Genital Neoplasms, Female / therapy*
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Immunotherapy / standards
  • Immunotherapy, Adoptive / methods
  • Molecular Targeted Therapy

Substances

  • Antineoplastic Agents, Immunological